36 documents found, page 1 of 4
Protective efficacy in a hamster model of a multivalent vaccine for human visce...
Fernández, L; Solana, JC; Sánchez, C; Jiménez, MÁ; Requena, JM; Coler, R; Reed, SG; Valenzuela, JG; Kamhawi, S; Oliveira, F; Fichera, E; Glueck, RVisceral leishmaniasis (VL) is the most severe clinical form of leishmaniasis, fatal if un-treated. Vaccination is the most cost-effective approach to disease control; however, to date, no vaccines against human VL have been made available. This work examines the efficacy of a novel vaccine consisting of the Leishmania membrane protein KMP11, LEISH-F3+ (a recombinant fusion protein, composed of epitopes of the ...
Design, synthesis and antiparasitic evaluation of click phospholipids
Magoulas, GE; Afroudakis, P; Georgikopoulou, K; Roussaki, M; Borsari, C; Fotopoulou, T; Santarém, N; Barrias, E; Tejera Nevado, P; Hachenberg, JA library of seventeen novel ether phospholipid analogues, containing 5-membered heterocyclic rings (1,2,3-triazolyl, isoxazolyl, 1,3,4-oxadiazolyl and 1,2,4-oxadiazolyl) in the lipid portion were designed and synthesized aiming to identify optimised miltefosine analogues. The compounds were evaluated for their in vitro antiparasitic activity against Leishmania infantum and Leishmania donovani intracellular ama...
Visceral dissemination of mucocutaneous leishmaniasis in a kidney transplant re...
Marques, N; Bustorff, M; Cordeiro-da-Silva, A; Pinto, AI; Santarém, N; Ferreira, F; Nunes, A; Cerqueira, A; Rocha, A; Ferreira, I; Tavares, I; Santos, JIntracellular protozoan of the genus Leishmania, endemic in the Mediterranean basin, are the cause of cutaneous (CL), mucocutaneous (MCL), and visceral leishmaniasis (VL). A 75-year-old woman was admitted nine years after a second kidney transplant (KT), due to persistent pancytopenia and fever. She presented edema and erythema of the nose in the last two years and an exophytic nodular lesion located on the lef...
Challenges in the serological evaluation of dogs clinically suspect for canine ...
Santarém, N; Sousa, S; Amorim, CMPG; Carvalho, NL; Carvalho, HL; Felgueiras, Ó; Brito, M; Cordeiro-da-Silva, ACanine leishmaniasis is a major veterinary issue and also a public health challenge due to its zoonotic potential. In this context, serological evaluation is essential for Canine leishmaniasis management. Several serological alternatives, such as rapid diagnostic tests, enzyme-linked immunosorbent assay (ELISA) and immunofluorescence antibody test (IFAT), are well established. In fact, the capacity of distinct ...
Engineering a vector-based pan-Leishmania vaccine for humans: proof of principle
Cecílio, P; Oristian, J; Meneses, C; Serafim, TD; Valenzuela, JG; Cordeiro-da-Silva, A; Oliveira, FLeishmaniasis is a spectrum of diseases transmitted by sand fly vectors that deposit Leishmania spp. parasites in the host skin during blood feeding. Currently, available treatment options are limited, associated with high toxicity and emerging resistance. Even though a vaccine for human leishmaniasis is considered an achievable goal, to date we still do not have one available, a consequence (amongst other fact...
Author Correction: Challenges in the serological evaluation of dogs clinically ...
Santarém, N; Sousa, S; Amorim, CMPG; Carvalho, NL; Carvalho, HL; Felgueiras, Ó; Brito, M; Cordeiro-da-Silva, AIn Figure 1C, D, and E the positive and negative controls are missing. The correct Figure 1 appears below.
More than just exosomes: distinct Leishmania infantum extracellular products po...
Perez-Cabezas, B; Santarém, N; Cecílio, P; Silva, C; Silvestre, R; A M Catita, J; Cordeiro-da-Silva, AThe use of secretion pathways for effector molecule delivery by microorganisms is a trademark of pathogenesis. Leishmania extracellular vesicles (EVs) were shown to have significant immunomodulatory potential. Still, they will act in conjunction with other released parasite-derived products that might modify the EVs effects. Notwithstanding, the immunomodulatory properties of these non-vesicular components and ...
Murine infection with bioluminescent Leishmania infantum axenic amastigotes app...
Costa, DM; Cecílio, P; Santarém, N; Cordeiro-da-Silva, A; Tavares, JLeishmaniasis is an important vector-borne neglected tropical disease caused by Leishmania parasites. Current anti-Leishmania chemotherapy is unsatisfactory, justifying the continued search for alternative treatment options. Herein, we demonstrate that luciferase-expressing Leishmania infantum axenic amastigotes, unlike promastigotes, are highly infectious to BALB/c mice and thus generate a robust bioluminescen...
The Use of Specific Serological Biomarkers to Detect CaniLeish Vaccination in Dogs
Lima, C; Santarém, N; Nieto, J; Moreno, J; Carrillo, E; Bartholomeu, D; Bueno, L; Fujiwara, R; Amorim, CMPG; Cordeiro-da-Silva, ACanine leishmaniosis (CanL) prevention in the Mediterranean basin is considered essential to stop human zoonotic visceral leishmaniasis. In this context, vaccination of dogs is expected to have a significant impact in disease control. CaniLeish® (Virbac Animal Health) is one of a few CanL vaccines that are at this moment licensed in Europe. This vaccine contains purified excreted-secreted proteins of Leishmania...
Understanding resistance vs. susceptibility in visceral leishmaniasis using mou...
Perez-Cabezas, B; Cecílio, P; Gaspar, TB; Gärtner, F; Vasconcellos, R; Cordeiro-da-Silva, AEvery year, up to 90,000 new cases of Visceral Leishmaniasis and 30,000 resultant deaths are estimated to occur worldwide. Such numbers give relevance to the continuous study of this complex form of the disease: a zoonosis and an anthroponosis; two known etiological agents (Leishmania infantum and L. donovani, respectively); with an estimated average ratio of 1 symptomatic per 10 asymptomatic individuals; and s...